The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications

Molecular Nutrition and Food Research

Volumn 58, Issue 8, 2014, Pages 1750-1759

  Camer, Danielle ^a   Yu, Yinghua ^a   Szabo, Alexander ^a,b   Huang, Xu Feng ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Cell signaling; Inflammation; Oleanolic acid derivatives; Oxidative stress

Indexed keywords

ANTIDIABETIC AGENT; OLEANOLIC ACID; TRITERPENE; URSOLIC ACID;

ANIMAL; BIOLOGICAL MODEL; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIET SUPPLEMENTATION; DIET THERAPY; HUMAN; METABOLISM; OXIDATIVE STRESS;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; OLEANOLIC ACID; OXIDATIVE STRESS; TRITERPENES;

EID: 84905396983     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300861     Document Type: Article

References (87)

1. Shaw, J. E., Sicree, R. A., Zimmet, P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87, 4-14.
2. Forouhi, N. G., Wareham, N. J., Epidemiology of diabetes. Medicine 2010, 38, 602-606.
3. Jager, S., Trojan, H., Kopp, T., Laszczyk, M. N., Scheffler, A., Pentacyclic triterpene distribution in various plants-rich sources for a new group of multi-potent plant extracts. Molecules 2009, 14, 2016-2031.
4. Patočka, J., Biologically active pentacyclic triterpenes and their current medicine signification. J. Appl. Biomed. 2012, 10, 7-12.
5. Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J. et al., Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 2011, 365, 327-336.
6. Jayaprakasam, B., Olson, L. K., Schutzki, R. E., Tai, M. H. et al., Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J. Agric. Food Chem. 2006, 54, 243-248.
7. de Melo, C. L., Queiroz, M. G., Fonseca, S. G., Bizerra, A. M. et al., Oleanolic acid, a natural triterpenoid improves blood glucose tolerance in normal mice and ameliorates visceral obesity in mice fed a high-fat diet. Chem. Biol. Interact. 2010, 185, 59-65.
8. Rao, V. S., de Melo, C. L., Queiroz, M. G. R., Lemos, T. L. G. et al., Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet. J. Med. Food 2011, 14, 1375-1382.
9. Gao, D., Li, Q., Li, Y., Liu, Z. et al., Antidiabetic and antioxidant effects of oleanolic acid from Ligustrum lucidum Ait in alloxan-induced diabetic rats. Phytother. Res. 2009, 23, 1257-1262.
10. Wang, X., Li, Y. L., Wu, H., Liu, J. Z. et al., Antidiabetic effect of oleanolic Acid: a promising use of a traditional pharmacological agent. Phytother. Res. 2011, 25, 1031-1040.
11. Huang, T. H., Yang, Q., Harada, M., Li, G. Q. et al., Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of cardiac endothelin-1 and nuclear factor-kappaB pathways. J. Cardiovasc. Pharmacol. 2005, 46, 856-862.
12. Kela, R., Srinivasan, B., Davies, M., Glycaemic management of type 2 diabetes. Medicine 2010, 38, 618-625.
13. Wang, Z. H., Hsu, C. C., Huang, C. N., Yin, M. C., Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. Eur. J. Pharmacol. 2010, 628, 255-260.
14. Liu, J., Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 1995, 49, 57-68.
15. Ramirez-Espinosa, J. J., Rios, M. Y., Lopez-Martinez, S., Lopez-Vallejo, F. et al., Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches. Eur. J. Med. Chem. 2011, 46, 2243-2251.
16. Huang, T. H., Peng, G., Kota, B. P., Li, G. Q. et al., Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br. J. Pharmacol. 2005, 145, 767-774.
17. Honda, T., Rounds, B. V., Gribble, G. W., Suh, N. et al., Design and synthesis of 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg. Med. Chem. Lett. 1998, 8, 2711-2714.
18. Honda, T., Rounds, B. V., Bore, L., Finlay, H. J. et al., Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 2000, 43, 4233-4246.
19. Liby, K., Hock, T., Yore, M. M., Suh, N. et al., The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005, 65, 4789-4798.
20. Suh, N., Honda, T., Finlay, H. J., Barchowsky, A. et al., Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 1998, 58, 717-723.
21. Yore, M. M., Liby, K. T., Honda, T., Gribble, G. W. et al., The synthetic triterpenoid 1-[2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol. Cancer Ther. 2006, 5, 3232-3239.
22. Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A. et al., Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol. 2011, 33, 469-476.
23. Jang, S. M., Yee, S. T., Choi, J., Choi, M. S. et al., Ursolic acid enhances the cellular immune system and pancreatic beta-cell function in streptozotocin-induced diabetic mice fed a high-fat diet. Int. Immunopharmacol. 2009, 9, 113-119.
24. Jung, S. H., Ha, Y. J., Shim, E. K., Choi, S. Y. et al., Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator. Biochem. J. 2007, 403, 243-250.
25. Zhang, W., Hong, D., Zhou, Y., Zhang, Y. et al., Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim. Biophys. Acta 2006, 1760, 1505-1512.
26. Lin, Z. H., Zhang, Y., Zhang, Y. N., Shen, H. et al., Oleanolic acid derivative NPLC441 potently stimulates glucose transport in 3T3-L1 adipocytes via a multi-target mechanism. Biochem. Pharmacol. 2008, 76, 1251-1262.
27. Cong, L. N., Chen, H., Li, Y. H., Zhou, L. X. et al., Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol. Endocrinol. 1997, 11, 1881-1890.
28. Hajduch, E., Alessi, D. R., Hemmings, B. A., Hundal, H. S., Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 1998, 47, 1006-1013.
29. Wang, Q. H., Somwar, R., Bilan, P. J., Liu, Z. et al., Protein kinase B Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol. Cell. Biol. 1999, 19, 4008-4018.
30. Smith, U., Carvalho, E., Mosialou, E., Beguinot, F. et al., PKB inhibition prevents the stimulatory effect of insulin on glucose transport and protein translocation but not the antilipolytic effect in rat adipocytes. Biochem. Biophys. Res. Commun. 2000, 268, 315-320.
31. Haruta, T., Morris, A. J., Rose, D. W., Nelson, J. G. et al., Insulin-stimulated Glut4 translocation is mediated by a divergent intracellular signaling pathway. J. Biol. Chem. 1995, 270, 27991-27994.
32. Charron, M. J., Katz, E. B., Olson, A. L., GLUT4 gene regulation and manipulation. J. Biol. Chem. 1999, 274, 3253-3256.
33. Zhang, Y. N., Zhang, W., Hong, D., Shi, L. et al., Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities. Bioorg. Med. Chem. 2008, 16, 8697-8705.
34. Yunoki, K., Sasaki, G., Tokuji, Y., Kinoshita, M. et al., Effect of dietary wine pomace extract and oleanolic acid on plasma lipids in rats fed high-fat diet and its DNA microarray analysis. J. Agric. Food Chem. 2008, 56, 12052-12058.
35. Jang, S. M., Kim, M. J., Choi, M. S., Kwon, E. Y. et al., Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metabolism 2010, 59, 512-519.
36. Na, M., Oh, W. K., Kim, Y. H., Cai, X. F. et al., Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum. Bioorg. Med. Chem. Lett. 2006, 16, 3061-3064.
37. Sun, T., Wang, Q., Yu, Z. G., Zhang, Y. et al., Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGF beta/Smad2 signaling. Chembiochem 2007, 8, 187-193.
38. Bence, K. K., Delibegovic, M., Xue, B., Gorgun, C. Z. et al., Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat. Med. 2006, 12, 917-924.
39. Dendooven, A., Ishola, D. A., Jr., Nguyen, T. Q., Van der Giezen, D. M. et al., Oxidative stress in obstructive nephropathy. Int. J. Exp. Pathol. 2011, 92, 202-210.
40. Truong, L. D., Gaber, L., Eknoyan, G., Obstructive uropathy. Contrib. Nephrol. 2011, 169, 311-326.
41. Chung, S., Yoon, H. E., Kim, S. J., Kim, S. J. et al., Oleanolic acid attenuates renal fibrosis in mice with unilateral ureteral obstruction via facilitating nuclear translocation of Nrf2. Nutr. Metab. 2014, 11, 1-11.
42. Liu, J., Liu, Y., Mao, Q., Klaassen, C. D., The effects of 10 triterpenoid compounds on experimental liver injury in mice. Fundam. Appl. Toxicol. 1994, 22, 34-40.
43. Ma, X. H., Zhao, Y. C., Yin, L., Xu, R. L. et al., Studies on the preventive and therapeutic effects of ursolic acid (UA) on acute hepatic injury in rats. Yao Xue. Xue. Bao. 1986, 21, 332-335.
44. Kawasaki, Y., Fujii, J., Miyazawa, N., Taniguchi, N., Tano, Y., Specific detections of the early process of the glycation reaction by fructose and glucose in diabetic rat lens. Invest. Ophth. Vis. Sci. 1999, 40, S522-S522.
45. Takeuchi, M., Yamagishi, S., Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med. Hypotheses 2004, 63, 453-455.
46. Tokita, Y., Hirayama, Y., Sekikawa, A., Kotake, H. et al., Fructose ingestion enhances atherosclerosis and deposition of advanced glycated end-products in cholesterol-fed rabbits. J. Atheroscler. Thromb. 2005, 12, 260-267.
47. Gugliucci, A., Bendayan, M., Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996, 39, 149-160.
48. Schleicher, E. D., Wagner, E., Nerlich, A. G., Increased accumulation of the glycoxidation product N-epsilon(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 1997, 99, 457-468.
49. Ziyadeh, F. N., Mogyorosi, A., Kalluri, R., Early and advanced non-enzymatic glycation products in the pathogenesis of diabetic kidney disease. Exp. Nephrol 1997, 5, 2-9.
50. Dunlop, M., Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. 2000, 58, S3-S12.
51. Beisswenger, P. J., Howell, S. K., Nelson, R. G., Mauer, M. et al., alpha-oxoaldehyde metabolism and diabetic complications. Biochem. Soc. T. 2003, 31, 1358-1363.
52. Chen, X. L., Kunsch, C., Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr. Pharm. Des. 2004, 10, 879-891.
53. Li, N., Nel, A. E., Role of the Nrf2-mediated signaling pathway as a negative regulator of inflammation: implications for the impact of particulate pollutants on asthma. Antioxid Redox Signal 2006, 8, 88-98.
54. Wang, X., Ye, X. L., Liu, R., Chen, H. L. et al., Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases. Chem. Biol. Interact 2010, 184, 328-337.
55. Itoh, K., Tong, K. I., Yamamoto, M., Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. 2004, 36, 1208-1213.
56. Yu, X., Kensler, T., Nrf2 as a target for cancer chemoprevention. Mutat. Res. 2005, 591, 93-102.
57. Wei, Y., Gong, J., Yoshida, T., Eberhart, C. G. et al., Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic. Biol. Med. 2011, 51, 216-224.
58. Nguyen, T., Yang, C. S., Pickett, C. B., The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic. Biol. Med. 2004, 37, 433-441.
59. Wu, Q. Q., Wang, Y., Senitko, M., Meyer, C. et al., Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J. Physiol. Renal. Physiol. 2011, 300, F1180-F1192.
60. Liu, J., Wu, K. C., Lu, Y. F., Ekuase, E. et al., NRF2 protection against liver injury produced by various hepatotoxicants. Oxid. Med. Cell. Longev. 2013, 2013, 305861.
61. Niture, S. K., Jaiswal, A. K., Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 2012, 287, 9873-9886.
62. Yu, M., Li, H., Liu, Q., Liu, F. et al., Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell Signal 2011, 23, 883-892.
63. Pitha-Rowe, I., Liby, K., Royce, D., Sporn, M., Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest. Ophthalmol. Vis. Sci. 2009, 50, 5339-5347.
64. Liu, J., Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 1995, 49, 57-68.
65. Pollier, J., Goossens, A., Oleanolic acid. Phytochemistry 2012, 77, 10-15.
66. Sultana, N., Ata, A., Oleanolic acid and related derivatives as medicinally important compounds. J. Enzyme Inhib. Med. Chem. 2008, 23, 739-756.
67. Petronelli, A., Pannitteri, G., Testa, U., Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009, 20, 880-892.
68. Liby, K. T., Yore, M. M., Sporn, M. B., Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 2007, 7, 357-369.
69. Lu, Y. F., Wan, X. L., Xu, Y., Liu, J., Repeated oral administration of oleanolic acid produces cholestatic liver injury in mice. Molecules 2013, 18, 3060-3071.
70. de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L. et al., Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 2013, 369, 2492-2503.
71. Osborn, O., Olefsky, J. M., The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012, 18, 363-374.
72. Gao, X., Belmadani, S., Picchi, A., Xu, X. et al., Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007, 115, 245-254.
73. Feingold, K. R., Soued, M., Staprans, I., Gavin, L. A. et al., Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J. Clin. Invest. 1989, 83, 1116-1121.
74. Grunfeld, C., Feingold, K. R., The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991, 3, 143-158.
75. Zhang, X., Zhang, G., Zhang, H., Karin, M. et al., Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell 2008, 135, 61-73.
76. Suh, S.-J., Jin, U.-H., Kim, K.-W., Son, J.-K. et al., Triterpenoid saponin, oleanolic acid 3-O-β-d-glucopyranosyl(1 → 3)-α-l-rhamnopyranosyl(1 → 2)-α-l-arabinopyranoside (OA) from Aralia elata inhibits LPS-induced nitric oxide production by down-regulated NF-κB in raw 264.7 cells. Archives of Biochemistry and Biophysics 2007, 467, 227-233.
77. Lu, J., Wu, D. M., Zheng, Y. L., Hu, B. et al., Ursolic acid improves high fat diet-induced cognitive impairments by blocking endoplasmic reticulum stress and IkappaB kinase beta/nuclear factor-kappaB-mediated inflammatory pathways in mice. Brain Behav. Immun. 2011, 25, 1658-1667.
78. Ahmad, R., Raina, D., Meyer, C., Kharbanda, S., Kufe, D., Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J. Biol. Chem. 2006, 281, 35764-35769.
79. Thimmulappa, R. K., Fuchs, R. J., Malhotra, D., Scollick, C. et al., Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid. Redox Signal. 2007, 9, 1963-1970.
80. Liby, K. T., Sporn, M. B., Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012, 64, 972-1003.
81. Bahia, P. K., Rattray, M., Williams, R. J., Dietary flavonoid (-)epicatechin stimulates phosphatidylinositol 3-kinase-dependent anti-oxidant response element activity and up-regulates glutathione in cortical astrocytes. J. Neurochem. 2008, 106, 2194-2204.
82. Hwang, Y. P., Jeong, H. G., The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett. 2008, 582, 2655-2662.
83. Lee, J. M., Hanson, J. M., Chu, W. A., Johnson, J. A., Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J. Biol. Chem. 2001, 276, 20011-20016.
84. Beyer, T. A., Xu, W., Teupser, D., auf dem Keller, U. et al., Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J. 2008, 27, 212-223.
85. Gunjima, K., Tomiyama, R., Takakura, K., Yamada, T. et al., 3, 4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway. J. Cell. Biochem. 2014, 115, 151-160.
86. Kim, J., Cha, Y. N., Surh, Y. J., A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat. Res. 2010, 690, 12-23.
87. Singh, S., Vrishni, S., Singh, B. K., Rahman, I. et al., Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic. Res. 2010, 44, 1267-1288.